Arsenal Biosciences

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers

PubMed author-name match

Trials

Studies that name Arsenal Biosciences as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:55 UTC. Open this list on ClinicalTrials.gov

Ph1/Ph2
NCT06245915 · AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Arsenal Biosciences, Inc. · active not recruiting · Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence · study director
Ph1
NCT05617755 · AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Arsenal Biosciences, Inc. · terminated · Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Fallopian Tube Neoplasms · study director

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:55 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

PubMed returned no clinical-trial papers for this author name.